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The onset and growth of subependymal giant cell astrocytoma (SEGA) in tuberous
sclerosis complex (TSC) typically occurs in childhood. There is minimal information on
SEGA evolution in adults with TSC. Of 2,211 patients enrolled in TOSCA, 220 of the 803
adults (27.4%) ever had a SEGA. Of 186 patients with SEGA still ongoing in adulthood,
153 (82.3%) remained asymptomatic, and 33 (17.7%) were reported to ever have
developed symptoms related to SEGA growth. SEGA growth since the previous scan
was reported in 39 of the 186 adults (21%) with ongoing SEGA. All but one patient with
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growing SEGA had mutations in TSC2. Fourteen adults (2.4%) were newly diagnosed
with SEGA during follow-up, and majority had mutations in TSC2. Our findings suggest
that surveillance for new or growing SEGA is warranted also in adulthood, particularly in
patients with mutations in TSC2.
Keywords: mTOR, registry, SEGA, TOSCA, tuberous sclerosis complex
INTRODUCTION
Tuberous sclerosis complex (TSC) is an autosomal dominant
disorder characterised by hamartomas in multiple organs, with
the brain being the most commonly affected organ (1, 2).
Subependymal giant cell astrocytoma (SEGA) occurs at the
foramen of Monro, with a reported lifetime prevalence between
5 and 24% (3, 4). Although SEGAs are generally benign and
non-infiltrative, these may grow, and obstruct cerebrospinal fluid
(CSF) flow, thereby increasing intracranial pressure. Typical
symptoms of growing SEGA include headaches, blurred vision,
nausea, vomiting, worsening of seizure control or new-onset
seizures, and sudden death from acute hydrocephalus (3, 5).
Diagnosis of SEGA has changed from pathology-based
to imaging-based (6, 7), but formal diagnostic criteria have
only been available since 2012, when an expert panel at
the International Tuberous Sclerosis Complex Consensus
Conference defined SEGA as a lesion at the caudothalamic
groove with a size of >1 cm in any direction or a subependymal
lesion at any location which has shown serial growth on
consecutive imaging regardless of size (7). All SEGA-related
studies performed before 2012 have been based on variable
criteria, thus limiting the value of comparison (8).
Onset and growth of SEGA has been reportedmost commonly
in the first two decades of life (9). In two of the largest series
of operated SEGAs, the mean age of surgical intervention was
9.7 years (10), and 11.6 years, (11) suggesting that growth
is most common at this age. SEGA have been reported in
neonates (9). Data on SEGA prevalence and growth in adults are
scarce. A retrospective case series of 16 patients with TSC who
required SEGA surgery, highlighted that SEGA can still become
symptomatic later in life (12).
Present guidelines recommend that patients with
asymptomatic SEGA diagnosed during childhood should
continue to be imaged periodically as adults to ensure that
there is no growth (13). Patients with large or growing SEGA
or with SEGA causing ventricular enlargement that are still
asymptomatic, should undergo MRI (magnetic resonance
imaging) scans more frequently, and such patients and their
families should be educated regarding the symptoms of raised
intracranial pressure (7).
Surgical resection (occasionally VP shunt alone) is the
recommended intervention for acutely symptomatic individuals,
while either surgical resection or medical therapy with
mammalian/mechanistic target of rapamycin (mTOR) inhibitors
can be effective for individuals with growing asymptomatic SEGA
(13). Treatment decisions should be based on multiple factors
such as the patient’s clinical condition, anatomic considerations
specific to SEGA, surgeon’s experience, experience of the centre
regarding use of mTOR inhibitors, prior history of SEGA
resection, other TSC-related comorbidities, and patient/parental
preference (7).
This is the first study evaluating prevalence, growth,
symptoms, and treatment patterns in a large prospective cohort
of adults with TSC-associated SEGA.
METHODS
TOSCA, a large-scale non-interventional study in patients with
TSC, was conducted at 170 sites in 31 countries. The study design
and methodology of TOSCA has been published previously (14).
The study enrolled patients of any age with TSC between August
2012 and November 2014 and followed for up to 5 years. Patient
data, including demographics, and information related to clinical
features of TSC across all organ systems, comorbidities and rare
manifestations, were collected at baseline and at regular visits
scheduled at a maximum interval of 1 year.
In this study, designed prior to the 2012 imaging-based
consensus, prevalence, and growth of SEGA were defined
as per clinical practice of the participating centres. We
evaluated SEGA manifestations among adult patients (>18
years) enrolled into the TOSCA study. SEGA-related questions
included in the case report form (CRF) were presence of
single or multiple SEGA, newly diagnosed SEGA, SEGA
growth, clinical signs, and symptoms associated with SEGA
and information regarding SEGA treatment. In addition,
possible associations of SEGA prevalence with genotype were
analysed using a Chi-square test. Statistical significance was set
at p-value < 0.05.
Statistics were descriptive considering the exploratory nature
of this study. Categorical data were reported as frequencies and
percentages, and continuous variables were expressed asmean (±
standard deviation) or asmedian (range), unless stated otherwise.
The study was designed and conducted in accordance
with the Good Clinical Practice principles, the Declaration
of Helsinki and all local regulations. The institutional review
board or ethics committee at each participating site approved
required TOSCA-related documents. Written informed
consent was obtained from all patients, parents or guardians
before enrolment.
RESULTS
A total of 2,214 patients with TSC were enrolled in TOSCA
study, and data were analysed for 2,211 patients. In the
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TABLE 1 | Demographics of adult patients with SEGA.
Characteristics Patients with SEGA
All adults (n = 220) >18 to ≤25 years
(n = 91)




Age at diagnosis of TSC, years; median (range) 4.0 (<1–48) 1.0 (<1–24) 4.0 (<1–37) 15.0 (<1–48)
Gender, n (%)
Male 98 (44.5) 35 (38.5) 46 (47.9) 17 (51.5)
Female 122 (55.5) 56 (61.5) 50 (52.1) 16 (48.5)
Patients with molecular testing, n (%) 96 (43.6) 40 (44.0) 41 (42.7) 15 (45.5)
Genetic Testing, n (%)
No mutation identified 12 (12.5) 6 (15.0) 3 (7.3) 3 (20.0)
TSC1 mutation 12 (12.5) 2 (5.0) 5 (12.2) 5 (33.3)
TSC2 mutation 69 (71.9) 31 (77.5) 31 (75.6) 7 (46.7)
Results not available* 5 (5.2) 1 (2.5) 1 (2.4) 0
Variation Type, n (%)
Pathogenic mutation 59 (61.5) 22 (55.0) 27 (65.9) 10 (66.7)
Variant of unknown significance 5 (5.2) 4 (10.0) 1 (2.4) 0
Both pathogenic mutation and variant of unknown significance 2 (2.1) 0 2 (4.9) 0
Results not available* 30 (31.3) 14 (35) 11 (26.8) 5 (33.3)
Patients with prenatal diagnosis, n (%) 1 (0.5) 1 (1.1) 0 0
Values are expressed as n (%), unless otherwise specified. * Include missing data and those results not made available due to legal/medical confidentiality statements.
SEGA, subependymal giant cell astrocytoma. TSC, tuberous sclerosis complex.
final analysis performed on data collected until August 2017,
a history of SEGA was reported in 30.3% (671/2,211; 332
males and 339 females) of patients. Other neuroimaging
features reported included cerebral white matter radial migration
lines in 25.5, cortical tubers in 87.2, and subependymal
nodules 82.9%.
Of the 803 adult patients included in the final analysis, a
history of SEGA was reported in 220 patients (27.4%). The
demographic of the adult patients with SEGA are shown in
Table 1. SEGA were ongoing during study in 186 (84.5%)
patients. Of these, multiple and bilateral SEGA were reported in
66 (35.5%), and 61 (32.8%) patients, respectively. SEGA growth
since previous scan was reported in 39 (21%). The median age at
SEGA diagnosis in this adult cohort was 20 years (range, <1–57
years), as compared to 7 years (range, <1–57 years) in the entire
TOSCA cohort.
The median interval between consecutive scans was 1 year
(range <1–34 years). During the study period (up to 5 years),
14 new diagnoses of SEGA were made (2.4% of total adults
minus those with history of SEGA). The oldest patient with
a newly reported SEGA was 57 years. Of the 186 adults
with ongoing SEGA, 153 (82.3%) remained asymptomatic, and
33 (17.7%) were reported to ever have developed symptoms
related to SEGA growth in the past, including primarily
increase in seizure frequency (15.6%), behavioural disturbance
(13.4%), and headache (10.8%), either alone or in combination
with other symptoms (Table 2). Over time, SEGA had been
treated with surgery in 55 out of 117 patients (47.0%) and
with mTOR-inhibitors in 46 out of 117 patients (39.3%).
Nine patients (7.7%) required a shunt for the management
of hydrocephalus.
SEGA were significantly more frequent in adults with a TSC2
mutation compared to those with a TSC1 mutation (35.2 vs.
15.6%, p < 0.0004). However, there was no significant difference
in multiple (p = 0.1158), bilateral (p = 0.1062), or growing
SEGA (p = 1.0000), and presence of SEGA-related symptoms
(p = 0.2598) between those with TSC1 and TSC2 mutation. The
median age at SEGA diagnosis was higher in patients with TSC1
mutations (29 years, range 9–51) compared to patients with TSC2
mutations (21 years, range <1–49), but this difference was non-
significant (Table 3). Furthermore, 12 of 14 adults with newly
diagnosed SEGA had mutations in TSC2 gene, while two had no
mutation identified.
DISCUSSION
To our knowledge, this is the first study to evaluate SEGA
prevalence, growth, symptoms, and current treatment modalities
in adults with TSC-associated SEGA. The international TOSCA
study allowed us to evaluate data from 803 adults (age>18 years),
220 of whom had SEGA (27.4%). During the 5 years follow-up
period of the study, 23.2% of adults reported that the SEGA was
still ongoing.
The occurrence of new SEGA after the age of 18 years was
relatively low (2.4%) but more common than previously thought
(7). In this cohort, age at SEGA diagnosis was as late as 57 years.
Newly diagnosed SEGA were associated with mutations in TSC2
in the large majority of cases (85.7%). Other risk factors such as
contrast enhancement of SEN in the caudo-thalamic groove were
beyond the scope of this study.
Another key finding was that SEGA growth since previous
scan (mean time of 1.5–2.3 years between previous scan
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>18 to ≤25 years
(n = 235)




Patients with history of SEGA 671 (30.3) 220 (27.4) 91 (38.7) 96 (27.9) 33 (14.7)
No. of patients with ongoing SEGA during the study, n 579 186 71 87 28
Multiple 240 (41.5) 66 (35.5) 24 (33.8) 33 (37.9) 9 (32.1)
Bilateral 236 (40.8) 61 (32.8) 21 (29.6) 30 (34.5) 10 (35.7)
Growing SEGA since previous scan*# 208 (35.9) 39 (21.0) 19 (26.8) 17 (19.5) 3 (10.7)
Signs and symptoms
None 476 (82.2) 153 (82.3) 57 (80.3) 72 (82.8) 24 (85.7)
Increase in seizure frequency 98 (16.9) 29 (15.6) 14 (19.7) 13 (14.9) 2 (7.1)
Behavioural disturbance 77 (13.3) 25 (13.4) 8 (11.3) 16 (18.4) 1 (3.6)
Regression/loss of cognitive skills 51 (8.8) 16 (8.6) 5 (7.0) 10 (11.5) 1 (3.6)
Headache 47 (8.1) 20 (10.8) 7 (9.9) 10 (11.5) 3 (10.7)
Ventriculomegaly 32 (5.5) 8 (4.3) 5 (7.0) 3 (3.4) 0
Increased intracranial pressure 24 (4.1) 10 (5.4) 6 (8.5) 2 (2.3) 2 (7.1)
Sleep disorder 22 (3.8) 7 (3.8) 1 (1.4) 6 (6.9) 0
Eye movement abnormalities 16 (2.8) 6 (3.2) 4 (5.6) 2 (2.3) 0
Visual impairment 10 (1.7) 4 (2.2) 3 (4.2) 1 (1.1) 0
Papilloedema 8 (1.4) 4 (2.2) 2 (2.8) 1 (1.1) 1 (3.6)
Neuroendocrine dysfunction 8 (1.4) 4 (2.2) 0 3 (3.4) 1 (3.6)
Other 28 (4.8) 7 (3.8) 4 (5.6) 3 (3.4) 0
Values are expressed as n (%), unless otherwise specified. *Median time from previous scan to last assessment was 1 year. #Growing of SEGA since previous scan was measured
among those with ongoing SEGA during the study. SEGA, subependymal giant cell astrocytoma.
and last assessment) was observed in 21% of our adult
patients. Although not negligible, this is less frequent compared
with children. In a cohort of 58 patients (33 children,
25 adults), Tsai et al. reported similar results, with SEGA
growth in children being significantly higher than in adults
(75.6 vs. 16.5%) (15).
The fact that SEGA may still grow during adulthood
emphasises the need for continuous surveillance even after the
age of 25 years. This was highlighted in the current guidelines that
recommend that patients with asymptomatic SEGA diagnosed
in childhood should continue to undergo periodical imaging
as adults to ensure that there is no growth. This highlights
the need for continued multidisciplinary follow-up, also at
adult age. Although newly occurring SEGA during adulthood
seem relatively rare and do not warrant systematic screening,
physicians should keep this possibility in mind when symptoms
potentially related to SEGA growth occur. Special attention
should be paid to adults with mutations in TSC2 since they seem
to be at a higher risk for newly occurring SEGA and SEGA
growth in adulthood as well as to individuals with intellectual
disability who might not be able to verbally express SEGA-
related symptoms. Importantly, certain SEGA-related symptoms
(especially early symptoms) are not limited to signs of increased
intracranial pressure, and therefore, parents and patients should
be informed about all relevant symptoms which require
referral for medical evaluation, particularly sudden behavioural
changes such as acute-onset and unexplained aggression,
academic difficulties or any other acute and unexplained
manifestations of TSC-associated neuropsychiatric disorders
(TAND) (16–18).
We acknowledge the limitations intrinsic to a large-scale,
international, non-interventional/observational study. These
included the fact that participants were recruited from expert
TSC centres around the world and the fact that data
on SEGA diagnosis, growth and SEGA-related symptoms
were collected as reported per clinical practice. However,
these limitations are, at least in part, offset by the large-
scale and “real-world” nature of the cohort across multiple
centres and countries. Being an observational study, detailed
information on the treatment initiated for SEGA at adult age
were not collected. The very low number of missing data
for SEGA reflects good quality of data collection for this
specific manifestation.
CONCLUSION
Findings from this large international study highlight the need
for continued monitoring for SEGA growth in adults with
ongoing SEGA. Clinicians and adults with TSC should be aware
of the potential new onset SEGA in adults with SEGA-related
symptoms, especially in the presence of mutations in TSC2.
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TABLE 3 | Clinical characteristics of SEGA in adults with mutations in TSC1
vs. TSC2.
Adults with TSC1
mutation (n = 77)
Adults with TSC2
mutation (n = 196)
p-value
Patients with history of SEGA 12 (15.6) 69 (35.2) 0.0004
Median (range) age at SEGA
diagnosis, years
29 (9–51) 21 (<1–49) 0.0599
No. of patients with ongoing
SEGA during the study
8 (66.7) 61 (88.4) 0.1317
Multiple 5 (62.5) 19 (31.1) 0.1158
Bilateral 5 (62.5) 18 (29.5) 0.1062
Growing SEGA since
previous scan
1 (12.5) 13 (21.3) 1.0000
Signs and Symptoms
None 5 (62.5) 49 (87.5) 0.3580
Increase in seizure
frequency
3 (37.5) 15 (28.3) 0.6243
Behavioural disturbance 1 (12.5) 14 (26.4) 1.0000
Headache 1 (12.5) 10 (18.9) 0.5753
Regression/loss of
cognitive skills
0 5 (9.4) 1.0000
Ventriculomegaly 0 4 (7.5) 1.0000
Increased intracranial
pressure
1 (12.5) 3 (5.7) 1.0000
Papilloedema 1 (12.5) 3 (5.7) 1.0000
Sleep disorder 0 2 (3.8) 1.0000
Eye movement
abnormalities
0 2 (3.8) 1.0000
Visual impairment 0 2 (3.8) 1.0000
Neuroendocrine
dysfunction
1 (12.5) 2 (3.8) 0.2408
Other 1 (12.5) 3 (5.7) 0.3098
Patients received treatment 8 (66.7) 37 (53.6) 0.0716
Values are expressed as n (%), unless otherwise specified.
SEGA, subependymal giant cell astrocytoma.
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biedribas Kliniskās izpētes Etikas komiteja, Ethics Committee
for Clinical Research; The First Affiliated Hospital of The
Fourth Military Medical University; Zhongshan hospital
Fudan University.
AUTHOR CONTRIBUTIONS
AJ, EB, MB, PC, JF, MF, CH, SJ, JL, AM, RN, VS, MS,
RT, BZ, and JK: designing the study, patient accrual, clinical
care, data interpretation, drafting, revising, final review, and
approval of the manuscript. TC, VC, LD’A, GBA, PV, CF,
FO’C, JQ, YT, and SY: designing the study, trial management,
data collection, data analysis, data interpretation, drafting,
revising, final review, and approval of the manuscript. RM:
designing the study, data analysis, data interpretation, drafting,
revising, final review, and approval of the manuscript. SS:
designing the study, trial statistician, data analysis, data
interpretation, drafting, revising, final review, and approval of
the manuscript.
FUNDING
The study was funded by Novartis Pharma AG. Novartis has
contributed to study design, data analysis, and the decision to
publish. Novartis authors reviewed the draft for submission.
ACKNOWLEDGMENTS
We thank patients and their families, investigators, and staff
from all participating sites. We thank Manojkumar Patel and
Pranitha Akula (Novartis Healthcare Pvt. Ltd.) for providing
medical editorial assistance with this manuscript.
TOSCA INVESTIGATORS
Japan: Nobuo Shinohara, Shigeo Horie, Masaya Kubota, Jun
Tohyama, Katsumi Imai, Mari Kaneda, Hideo Kaneko, Yasushi
Uchida, Tomoko Kirino, Shoichi Endo, Yoshikazu Inoue,
Katsuhisa Uruno; Turkey: Ayse Serdaroglu, Zuhal Yapici, Banu
Anlar, Sakir Altunbasak; Russia: Olga Lvova, Oleg Valeryevich
Belyaev, Oleg Agranovich, Elena Vladislavovna Levitina, Yulia
Vladimirovna Maksimova, Antonina Karas; China: Yuwu Jiang,
Liping Zou, Kaifeng Xu, Yushi Zhang, Guoming Luan, Yuqin
Zhang, Yi Wang, Meiling Jin, Dingwei Ye, Weiping Liao, Liemin
Zhou, Jie Liu, Jianxiang Liao, Bo YAN, Yanchun Deng, Li Jiang,
Zhisheng Liu, Shaoping Huang, Hua Li; Korea: Kijoong Kim;
Taiwan: Pei-Lung Chen, Hsiu-Fen Lee, Jeng-Dau Tsai, Ching-
Shiang Chi, Chao-Ching Huang; Australia: Kate Riney, Deborah
Yates, Patrick Kwan; Thailand: Surachai Likasitwattanakul,
Charcrin Nabangchang, Lunliya Thampratankul Krisnachai
Chomtho, Kamornwan Katanyuwong, Somjit Sriudomkajorn;
South Africa: Jo Wilmshurst; Israel: Reeval Segel, Tal Gilboa,
Frontiers in Neurology | www.frontiersin.org 6 August 2019 | Volume 10 | Article 821
Jansen et al. SEGA in Adults With TSC
Michal Tzadok, Aviva Fattal- Valevski; Greece: Panagiotis
Papathanasopoulos, Antigone Syrigou Papavasiliou, Stylianos
Giannakodimos, Stylianos Gatzonis, Evangelos Pavlou, Meropi
Tzoufi; Netherlands: A.M.H. Vergeer; Belgium: Marc Dhooghe,
Hélène Verhelst, Filip Roelens, Marie Cecile Nassogne,
Pierre Defresne, Liesbeth De Waele, Patricia Leroy, Nathalie
Demonceau, Benjamin Legros, Patrick Van Bogaert, Berten
Ceulemans, Lina Dom; France: Pierre Castelnau, Anne De Saint
Martin, Audrey Riquet, Mathieu Milh, Claude Cances, Jean-
Michel Pedespan, Dorothee Ville, Agathe Roubertie, Stéphane
Auvin, Patrick Berquin, Christian Richelme, Catherine Allaire,
Sophie Gueden, Sylvie Nguyen The Tich, Bertrand Godet; Spain:
Maria Luz Ruiz Falco Rojas, Jaume Campistol Planas, Antonio
Martinez Bermejo, Patricia Smeyers Dura, Susana Roldan
Aparicio, Maria Jesus Martinez Gonzalez, Javier Lopez Pison,
Manuel Oscar Blanco Barca, Eduardo Lopez Laso, Olga Alonso
Luengo, Francisco Javier Aguirre Rodriguez, Ignacio Malaga
Dieguez, Ana Camacho Salas, Itxaso Marti Carrera, Eduardo
Martinez Salcedo, Maria Eugenia Yoldi Petri, Ramon Cancho
Candela; Portugal: Ines da Conceicao Carrilho, Jose Pedro Vieira,
José Paulo da Silva Oliveira Monteiro, Miguel Jorge Santos de
Oliveira Ferreira Leao, Catarina Sofia Marceano Ribeiro Luis,
Carla Pires Mendonca; Lithuania: Milda Endziniene; Latvia:
Jurgis Strautmanis; Estonia: Inga Talvik; Italy: Maria Paola
Canevini, Antonio Gambardella, Dario Pruna, Salvatore Buono,
Elena Fontana, Bernardo Dalla Bernardina; Romania: Carmen
Burloiu, Iuliu Stefan Bacos Cosma, Mihaela Adela Vintan, Laura
Popescu; Czech Republic: Karel Zitterbart; Slovakia: Jaroslava
Payerova, Ladislav Bratsky, Zuzana Zilinska; Austria: Ursula
Gruber-Sedlmayr, Matthias Baumann, Edda Haberlandt, Kevin
Rostasy, Ekaterina Pataraia; United Kingdom: Frances Elmslie,
Clare Ann Johnston, Pamela Crawford; Denmark: Peter Uldall;
Sweden: Maria Dahlin, Paul Uvebrant, Olof Rask; Norway: Marit
Bjoernvold, Eylert Brodtkorb, Andreas Sloerdahl, Ragnar Solhoff,
Martine Sofie Gilje Jaatun; Poland: Marek Mandera, Elzbieta
Janina Radzikowska, Mariusz Wysocki; Germany: Michael
Fischereder, Gerhard Kurlemann, Bernd Wilken, Adelheid
Wiemer-Kruel, Klemens Budde, Klaus Marquard, Markus Knuf,
Andreas Hahn, Hans Hartmann, Andreas Merkenschlager,
Regina Trollmann.
REFERENCES
1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. (2008)
372:657–68. doi: 10.1016/S0140-6736(08)61279-9
2. Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric
aspects of tuberous sclerosis complex. Lancet Neurol. (2015) 14:733–
45. doi: 10.1016/S1474-4422(15)00069-1
3. Goh S, Butler W, Thiele EA. Subependymal giant cell tumors
in tuberous sclerosis complex. Neurology. (2004) 63:1457–
61. doi: 10.1212/01.WNL.0000142039.14522.1A
4. Kingswood JC, d’Augeres GB, Belousova E, Ferreira JC, Carter T, Castellana
R, et al. TuberOus SClerosis registry to increase disease Awareness
(TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. (2017)
12:2. doi: 10.1186/s13023-016-0553-5
5. Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Duyndam DA, Zonnenberg
BA, Prokop M. Prevalence of subependymal giant cell tumors in patients
with tuberous sclerosis and a review of the literature. Eur J Neurol. (2009)
16:691–6. doi: 10.1111/j.1468-1331.2009.02567.x
6. Roach ES, Smith M, Huttenlocher P, Bhat M, Alcorn D, Hawley L.
Diagnostic criteria: tuberous sclerosis complex. report of the diagnostic
criteria committee of the national tuberous sclerosis association. J Child
Neurol. (1992) 7:221–4. doi: 10.1177/088307389200700219
7. Roth J, Roach ES, Bartels U, Jozwiak S, Koenig MK, Weiner HL,
et al. Subependymal giant cell astrocytoma: diagnosis, screening, and
treatment. Recommendations from the International tuberous sclerosis
complex consensus conference 2012. Pediatr Neurol. (2013) 49:439–
44. doi: 10.1016/j.pediatrneurol.2013.08.017
8. Chan DL, Calder T, Lawson JA, Mowat D, Kennedy SE. The natural history of
subependymal giant cell astrocytomas in tuberous sclerosis complex: a review.
Rev Neurosci. (2018) 29:295–301. doi: 10.1515/revneuro-2017-0027
9. Kotulska K, Borkowska J, Mandera M, Roszkowski M, Jurkiewicz E,
Grajkowska W, et al. Congenital subependymal giant cell astrocytomas in
patients with tuberous sclerosis complex. Childs Nerv Syst. (2014) 30:2037–
42. doi: 10.1007/s00381-014-2555-8
10. Kotulska K, Borkowska J, Roszkowski M, Mandera M, Daszkiewicz P,
Drabik K, et al. Surgical treatment of subependymal giant cell astrocytoma
in tuberous sclerosis complex patients. Pediatr Neurol. (2014) 50:307–
12. doi: 10.1016/j.pediatrneurol.2013.12.004
11. Sun P, Kohrman M, Liu J, Guo A, Rogerio J, Krueger D. Outcomes of
resecting subependymal giant cell astrocytoma (SEGA) among patients
with SEGA-related tuberous sclerosis complex: a national claims database
analysis. Curr Med Res Opin. (2012) 28:657–63. doi: 10.1185/03007995.2012.6
58907
12. Amin S, Carter M, Edwards RJ, Pople I, Aquilina K, Merrifield J, et
al. The outcome of surgical management of subependymal giant cell
astrocytoma in tuberous sclerosis complex. Eur J Paediatr Neurol. (2013)
17:36–44. doi: 10.1016/j.ejpn.2012.10.005
13. Krueger DA, Northrup H. Tuberous sclerosis complex
surveillance and management: recommendations of the 2012
international tuberous sclerosis complex consensus conference.
Pediatr Neurol. (2013) 49:255–65. doi: 10.1016/j.pediatrneurol.
2013.08.002
14. Kingswood JC, Bruzzi P, Curatolo P, de Vries PJ, Fladrowski C, Hertzberg
C, et al. TOSCA - first international registry to address knowledge
gaps in the natural history and management of tuberous sclerosis
complex. Orphanet J Rare Dis. (2014) 9:182. doi: 10.1186/s13023-014-
0182-9
15. Tsai JD, Wei CC, Tsao TF, Hsiao YP, Tsai HJ, Yang SH, et al. Association
between the growth rate of subependymal giant cell astrocytoma and age
in patients with tuberous sclerosis complex. Childs Nerv Syst. (2016) 32:89–
95. doi: 10.1007/s00381-015-2947-4
16. de Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo
P, et al. TSC-associated neuropsychiatric disorders (TAND): findings
from the TOSCA natural history study. Orphanet J Rare Dis. (2018)
13:157. doi: 10.1186/s13023-018-0901-8
17. Wilde L, Eden K, de Vries P, Moss J, Welham A, Oliver C. Self-
injury and aggression in adults with tuberous sclerosis complex:
frequency, associated person characteristics, and implications for
assessment. Res Dev Disabil. (2017) 64:119–30. doi: 10.1016/j.ridd.2017.
03.007
18. de Vries PJ, Wilde L, de Vries MC, Moavero R, Pearson DA,
Curatolo P. A clinical update on tuberous sclerosis complex-associated
neuropsychiatric disorders (TAND). Am J Med Genet Part C. (2018)
178:309–20. doi: 10.1002/ajmg.c.31637
Conflict of Interest Statement: AJ, EB, TC, VC, PC, GBA, PV, JK, JF, MF, CF,
CH, SJ, RN, FO’C, JQ, MS, RT, JL, AM, SY, MB, and BZ received honoraria
and support for travel from Novartis. VC received personal fees for consulting,
lecture fees, and travel from Actelion, Bayer, Biogen Idec, Boehringer Ingelheim,
Gilead, GSK, MSD, Novartis, Pfizer, Roche, and Sanofi; grants from Actelion,
Boehringer Ingelheim, GSK, Pfizer, and Roche; personal fees for developing
educational material from Boehringer Ingelheim and Roche. PV has been on the
Frontiers in Neurology | www.frontiersin.org 7 August 2019 | Volume 10 | Article 821
Jansen et al. SEGA in Adults With TSC
study steering group of the EXIST-1, 2, and 3 studies sponsored by Novartis and
co-PI on two investigator-initiated studies part-funded by Novartis. RN received
grant support, paid to her institution, from Eisai and lectures fees from Nutricia,
Eisai, Advicenne, and GW Pharma. YT received personal fee from Novartis for
lecture and for copyright of referential figures from the journals and received
grant from Japanese government for intractable epilepsy research. SJ was partly
financed by the EC Seventh Framework Programme (FP7/2007-2013; EPISTOP,
grant agreement no. 602391), the Polish Ministerial funds for science (years
2013–2018) for implementation of international co-financed project and the grant
EPIMARKER of the Polish National Center for Research and Development No
STRATEGMED3/306306/4/2016. JK, PC, CH, JL, and JQ received research grant
from Novartis. RM and SS are employees of Novartis, while LD’A was a Novartis
employee at the time of manuscript concept approval. This study was funded by
Novartis Pharma AG. All authors approved the final version of the manuscript
prior to submission.
Copyright © 2019 Jansen, Belousova, Benedik, Carter, Cottin, Curatolo, D’Amato,
Beaure d’Augères, de Vries, Ferreira, Feucht, Fladrowski, Hertzberg, Jozwiak,
Lawson, Macaya, Marques, Nabbout, O’Callaghan, Qin, Sander, Sauter, Shah,
Takahashi, Touraine, Youroukos, Zonnenberg and Kingswood. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) and the copyright owner(s) are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Neurology | www.frontiersin.org 8 August 2019 | Volume 10 | Article 821
